Pan-canadian public health network council report and policy recommendations on the use of antivirals for prophylaxis during an influenza pandemic

June 2007

PDF Version
135 Pages (640 KB)

Table of Contents

• Executive Summary
• Acronyms
• Introduction
  • 1. Task Group on Antivirals for Prophylaxis (TGAP) - Origins
  • 2. Antiviral Strategy Goals and TGAP Assumptions
  • 3. Report Outline
• Background and Current Status of Antivirals in Canada
• Key Considerations and Expert Reviews
  • 1. Scientific Considerations
  • 2. Program Implementation – Health System/Logistical Considerations
  • 3. Legal Considerations
  • 4. Ethical/Societal Considerations
  • 5. Federal/Provincial/Territorial (F/P/T) Considerations
  • 6. International Trends Regarding Antivirals for Prophylaxis
  • 7. Citizen and Stakeholder Deliberative Dialogues
  • 8. First Nations and Inuit Considerations
  • 9. Economic Considerations
• Process For Recommendation Development
  • 1. Background and Assumptions
  • 2. Synthesis of Considerations
  • 3. Potential Target Groups for Antiviral Prophylaxis
  • 4. Uses of Antivirals during an Influenza Pandemic
• Recommendations
  • 1. Recommendation for Use of Antivirals for Prophylaxis
  • 2. Corollary Recommendations
• Conclusions
• Annex 1: Ministerial Decisions/Directions regarding Antivirals in the context of pandemic planning
• Annex 2: Task Group on Antivirals for Prophylaxis
• Annex 3: Background Reports and Expert Reviews
  • Annex 3.1–Scientific Considerations on the Prophylactic Use of Antivirals in an Influenza Pandemic
  • Annex 3.2–Health System/Logistical Considerations
  • Annex 3.3–Legal considerations for the purchase and stockpiling of antivirals for prophylaxis by governments for use during pandemic influenza
  • Annex 3.4–Ethical/Societal Considerations on the Prophylactic Use of Antivirals in an Influenza Pandemic
  • Annex 3.5– F/P/T Considerations in the Use of Antivirals for Prophylaxis
  • Annex 3.6–International Trends Regarding Antivirals for Prophylaxis
  • Annex 3.7–Report on Citizen and Stakeholder Deliberative Dialogues on the Use of Antivirals for Prophylaxis
  • Annex 3.8–First Nations and Inuit Considerations
• Annex 4: WHO / CPIP Pandemic Phase Definitions
• References

[Next]